Acorda Therapeutics Inc (NASDAQ:ACOR) Shorts Decreased By 5.4%

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Corporate Logo

Big Money Sentiment increased to 1.45 in 2018 Q2. It has change of 0.02, from 2018Q1’s 1.43. The ratio increased due to Acorda Therapeutics, Inc. positioning: 16 sold and 46 reduced. 34 funds bought holdings and 56 increased holdings. Investors holded 48.53 million in 2018Q1 but now own 47.68 million shares or 1.76% less.
Systematic Fincl Management Limited Partnership has 0.03% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 45,935 shs. Wells Fargo & Mn holds 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 73,243 shs. 173 are held by Mutual Of America Management Ltd Liability. Wellington Mngmt Group Llp holds 261,956 shs. Diamond Hill Mngmt Inc holds 13,774 shs or 0% of its capital. Swiss Bancorporation invested 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Metropolitan Life Insur Ny reported 0% of its capital in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Comerica Bankshares accumulated 49,678 shs. Moreover, Partner Investment Lp has 0.64% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 27,704 shs. Meeder Asset Mgmt stated it has 891 shs or 0% of all its holdings. 60,160 are held by Great West Life Assurance Can. Parkside Bancorporation And Trust accumulated 42 shs. Invesco Ltd has 1.31M shs. Tudor Invest Et Al has 0.01% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Mackenzie Finance Corporation reported 65,195 shs or 0% of all its holdings.

Acorda Therapeutics, Inc. had 17 sales and 0 buys since June 7, 2018. This’s net activity of $45.28 million. On Thursday, June 28 Shares for $163,140 were sold by Sabella Lauren M. On Thursday, June 7 the insider LAWRENCE DAVID sold $704,783. Another trade for 5,000 shs valued at $148,050 was made by BLANK BURKHARD on Monday, July 2. SMITH IAN F also sold $785,568 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Friday, June 15. 1,904 shs valued at $38,034 were sold by Randall Lorin on Monday, November 26.

Acorda Therapeutics Inc (NASDAQ:ACOR) recorded a decrease of 5.4% in shorted shares. It was announced in December by FINRA the 4.26 million shorted shares on ACOR. The 4.50M previous shares are down with 5.4%. 14 days will cost ACOR with 313,400 average volume to restore its previous position. Acorda Therapeutics Inc float short is 10.84%.

The stock decreased 0.96% or $0.18 during the last trading session, hitting $18.63.Acorda Therapeutics, Inc. has volume of 686,334 shares. Since December 8, 2017 ACOR has declined 20.26% and is downtrending. ACOR underperformed by 35.88% the S&P500.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.The firm is worth $886.01 million. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.Currently it has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

Total analysts of 3 have positions in Acorda Therapeutics (NASDAQ:ACOR) as follows: 1 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 33%. Since June 11, 2018 according to StockzIntelligence Inc Acorda Therapeutics has 4 analyst reports. In Friday, October 5 report Stifel Nicolaus maintained it with “Hold” rating and $19 target. On Monday, June 11 H.C. Wainwright maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) rating. H.C. Wainwright has “Buy” rating and $3100 target. On Tuesday, August 7 the stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) earned “Hold” rating by Stifel Nicolaus.

For more Acorda Therapeutics, Inc. (NASDAQ:ACOR) news released briefly go to:,,, or The titles are as follows: “Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up – Nasdaq” released on November 01, 2018, “Noteworthy Monday Option Activity: ALNY, ACOR, EROS – Nasdaq” on September 10, 2018, “Acorda Has Suffered 2 Setbacks, Both Of Which Can Be Dealt With – Seeking Alpha” with a publish date: September 18, 2018, “Premarket analyst action – healthcare – Seeking Alpha” and the last “Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today’s Competitive Landscape – Nasdaq” with publication date: November 08, 2018.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.